Stereotaxis, Inc. (STXS) Form 8-K — May 12, 2026
Stereotaxis, Inc. reported a revenue of $6.3 million for the first quarter of 2026, a 15.8% decline from $7.5 million in the same period last year. The company's net loss was $5.9 million, slightly worse than the $5.8 million loss in the prior year. Despite the revenue decline, Stereotaxis achieved significant regulatory milestones, including FDA approval for the MAGiC catheter and FDA clearance for the Synchrony digital surgery system.
Key figures
- Eps
- -0.06
- Eps Beat
- 0
- Revenue
- 6291
- Net Income
- -5861
- Total Debt
- 0
- Revenue Yoy
- -15.8%
- Cash Position
- 14616
Price after filing
1 day: -3.6%7 days: -9.9%30 days: -5.7%
Close on the filing date to close N calendar days later (from $1.92). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.